Real-world treatment patterns and outcomes in HER2-low, HR+ metastatic breast cancer patients previously treated with endocrine therapy in the United States

Background: Up to 60% of metastatic breast cancer (mBC) cases historically classified as human epidermal growth factor receptor 2 (HER2)-negative may be HER2-low, expanding options towards new HER2 targeted treatments. Greater understanding of the current therapeutic journey of this population can h...

Полное описание

Библиографические подробности

Главные авторы:	Shanu Modi, Danalyn Byng, Suyuan Zhang, Yan Xiong, Shannon Hunter, Kyle Dunton, Tara Harding, William Jacot
Формат:	Artigo
Язык:	Inglês
Опубликовано:	Elsevier 2026-04-01
Серии:	Breast
Предметы:	Metastatic breast cancer Real-world evidence HER2-Low HR+ Trastuzumab deruxtecan
Online-ссылка:	http://www.sciencedirect.com/science/article/pii/S0960977626000317
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!